readthroughSign in
CompanyMLTXNasdaqZug, V8

MoonLake Immunotherapeutics AG

Clinical-stage biotech company developing SLK, a tri-specific Nanobody inhibiting IL-17A and IL-17F, for inflammatory skin and joint diseases including hidradenitis suppurativa.

424B3Nov 6Latest SEC filing
Nov 2Latest story